Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]
News [7787]
Articles [63]
Editorials [9]
Conferences [208]
elearning [49]
Comment: Advances in lung cancer presented at ASCO 2014
Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland
Comment: Advances in lung cancer presented at ASCO 2014 ( Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland )
1 Jun 2014
Medyczne nowości w raku gruczołu krokowego
Prof Piotr Jan Wysocki - Poznan University of Medical Sciences, Poznan, Poland
Medyczne nowości w raku gruczołu krokowego ( Prof Piotr Jan Wysocki - Poznan University of Medical Sciences, Poznan, Poland )
1 Jun 2014
Ramucirumab plus docetaxel extends survival in advanced NSCLC
Dr Maurice Pérol - Centre Léon Bérard, Lyon, France
Ramucirumab plus docetaxel extends survival in advanced NSCLC ( Dr Maurice Pérol - Centre Léon Bérard, Lyon, France )
31 May 2014
Targeted drug combo, cediranib plus olaparib, significantly increases...
Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA
Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer ( Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA )
31 May 2014
Ibrutinib significantly delays disease progression and extends survival in...
Dr John Byrd - The Ohio State University, Columbus, USA
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )
31 May 2014
Lenvatinib yields high response rates and delays progression in radioiodine...
Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France
Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )
31 May 2014
Second-line treatment with ramucirumab plus docetaxel extends survival in...
Dr Maurice Pérol - Centre Léon Bérard, Lyon, France
Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC ( Dr Maurice Pérol - Centre Léon Bérard, Lyon, France )
31 May 2014
Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer
Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA
Cediranib plus olaparib significantly increases PFS in recurrent ovarian cancer ( Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA )
31 May 2014
Ibrutinib significantly delays disease progression and extends survival in...
Dr John Byrd - The Ohio State University, Columbus, USA
Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )
31 May 2014
Emerging pathways in immunotherapy
Prof Christopher Höller - Medical University of Vienna, Vienna, Austria
Emerging pathways in immunotherapy ( Prof Christopher Höller - Medical University of Vienna, Vienna, Austria )
20 May 2014
Checkpoint blockade: a concept or already a reality?
Prof Paolo Ascierto - National Cancer Institute 'Foundazione G. Pascale'...
Checkpoint blockade: a concept or already a reality? ( Prof Paolo Ascierto - National Cancer Institute 'Foundazione G. Pascale', Naples, Italy )
20 May 2014
Cancer evasion of the immune system: the fundamentals
Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland
Cancer evasion of the immune system: the fundamentals ( Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland )
20 May 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation